Impact of Previous Bacille Calmette-Guérin Failure Pattern on Subsequent Response to Bacille Calmette-Guérin Plus Interferon Intravesical Therapy

Urology

Volumn 71, Issue 2, 2008, Pages 297-301

  Gallagher, Brian L ^a   Joudi, Fadi N ^a   Maymí, José L ^a   O'Donnell, Michael A ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCG VACCINE;

ARTICLE; BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT RESPONSE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; BCG VACCINE; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; RETROSPECTIVE STUDIES; TREATMENT FAILURE; URINARY BLADDER NEOPLASMS;

EID: 39549085118     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.09.050     Document Type: Article

References (24)

1. Kurth K.H., Bouffioux C., Sylvester R., et al., EORTC Genitourinary Group. Treatment of superficial bladder tumors: achievements and needs. Eur Urol 37 suppl 3 (2000) 1-9
2. Herr H.W., Pinsky C.M., Whitmore Jr. W.F., et al. Long-term effect of intravesical bacillus Calmette-Guérin on flat carcinoma in situ of the bladder. J Urol 135 (1986) 265-267
3. Melekos M.D., Chionis H., Pantazakos A., et al. Intravesical bacillus Calmette-Guérin immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule. J Urol 149 (1993) 744-748
4. Sylvester R.J., van der Meijden A.P., Witjes J.A., et al. Bacillus Calmette-Guérin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 174 (2005) 86-92
5. van der Meijden A.P., Sylvester R.J., Oosterlinck W., et al. Maintenance Bacillus Calmette-Guérin for Ta T1 bladder tumours is not associated with increased toxicity: results from a European Organization for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 44 (2003) 429-434
6. Lamm D.L., and Griffith J.G. Intravesical therapy: does it affect the natural history of superficial bladder cancer?. Semin Urol 10 (1992) 39-44
7. Thalmann G.N., Sermier A., Rentsch C., et al. Urinary interleukin-8 and -18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guérin. J Urol 164 (2000) 2129-2133
8. Watanabe E., Matsuyama H., Matsuda K., et al. Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guérin immunotherapy for carcinoma in situ of the bladder. Cancer Immunol Immunother 52 (2003) 481-486
9. Saint F., Kurth N., Maille P., et al. Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Guérin response of superficial bladder cancer during induction course and maintenance therapy. Int J Cancer 107 (2003) 434-440
10. Laufer M., Kaver I., Sela B., et al. Elevated urinary fibronectin levels after transurethral resection of bladder tumor: a possible role in patients failing therapy with bacillus Calmette-Guérin. BJU Int 84 (1999) 428-432
11. Lebret T., Watson R.W., Molinié V., et al. HSP90 expression: a new predictive factor for BCG response in stage Ta-T1 grade 3 bladder tumors. Eur Urol 51 (2007) 161-167
12. O'Donnell M.A., and Boehle A. Treatment options for BCG failures. World J Urol 24 (2006) 481-487
13. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19 (2001) 666-675
14. Mungan N.A., and Witjes J.A. Bacille Calmette-Guérin in superficial transitional cell carcinoma. Br J Urol 82 (1998) 213-223
15. Luo Y., Chen X., Downs T.M., et al. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy. J Immunol 162 (1999) 2399-2405
16. Punnen S.P., Chin J.L., and Jewett M.A. Management of bacillus Calmette-Guérin (BCG) refractory superficial bladder cancer: results with intravesical BCG and interferon combination therapy. Can J Urol 10 (2003) 1790-1795
17. Lam J.S., Benson M.C., O'Donnell M.A., et al. Bacillus Calmette-Guérin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity. Urol Oncol 21 (2003) 354-360
18. Joudi F.N., and O'Donnell M.A. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 24 (2006) 344-348
19. Herr H., and Dalbagni G. Defining bacillus Calmette-Guérin refractory superficial bladder tumors. J Urol 169 (2003) 1706-1708
20. Bui T.T., and Schellhammer P.F. Additional bacillus Calmette-Guérin therapy for recurrent transitional cell carcinoma after initial complete response. Urology 49 (1997) 687-690
21. Joudi F.N., Smith B.J., O'Donnell M.A., et al. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol 175 (2006) 1634-1639
22. Bretton P.R., Herr H.W., Kimmel M., et al. The response of patients with superficial bladder cancer to a second course of intravesical bacillus Calmette-Guérin. J Urol 143 (1990) 710-713
23. Lockyer C.R., Sedgwick J.E., and Gillatt D.A. Beware the BCG failures: a review of one institution's results. Eur Urol 42 (2002) 542-546
24. Martinez-Pineiro J.A., Martinez-Pineiro L., Solsona E., et al. Has a 3-fold decreased dose of bacillus Calmette-Guérin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose?. Results of a prospective randomized trial. J Urol 174 (2005) 1242-1247